Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03269695 · ClinicalTrials.gov registry record · Phase 2
Efficacy, Safety and Tolerability of PF-06687234 as Add-on Therapy to Infliximab in Active UC Subjects Not in Remission.
A Phase 2 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT03269695 is a Phase 2 study that was terminated before completion, run by Pfizer. The registered enrollment target is 20 participants.
The verdict
NCT03269695, a Phase 2 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if PF-06687234 is effective and safe as add-on therapy to infliximab in subjects with active ulcerative colitis who are not in remission.
Interventions
- DRUG Placebo
- DRUG PF-06687234
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2017-12-20 |
| Est. Completion | 2021-01-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03269695
The ClinicalTrials.gov registry entry for NCT03269695 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03269695 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03269695 about?
NCT03269695 is a clinical study titled "Efficacy, Safety and Tolerability of PF-06687234 as Add-on Therapy to Infliximab in Active UC Subjects Not in Remission.". The purpose of this study is to determine if PF-06687234 is effective and safe as add-on therapy to infliximab in subjects with active ulcerative colitis who are not in remission.
What is the current status of trial NCT03269695?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2017-12-20. Estimated completion is 2021-01-07.
What interventions are being tested in trial NCT03269695?
The interventions under investigation include: Placebo (DRUG), PF-06687234 (DRUG).
Who is sponsoring clinical trial NCT03269695?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.